Clinical Trial

Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma

Study acronym: Mel73
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This research study is testing a decision aid to help patients think through whether to have sentinel lymph node biopsy for melanoma. Sentinel lymph node biopsy (SLNB) can be a difficult decision for some patients because the potential benefits and risks may not be clear. This study is being done to learn whether providing structured, easy-to-understand information helps patients feel more informed and less uncertain about their decision. Patients in this study will be given a paper decision aid (DA). Patients will be given other short questionnaires to complete before and after the decision aid.
Trial Details
NCT Number NCT07653087
Lead Sponsor University of Virginia
Conditions Sentinel Lymph Node Biopsy (SLNB), Melanoma (Skin Cancer)
Enrollment 66 participants
Start Date 2026-06
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17